Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1992 Aug;18:S96–101.

Poor prognosis neuroblastoma: is screening the answer?

A W Craft 1, L Parker 1
PMCID: PMC2149668  PMID: 1503935

Abstract

Neuroblastoma is one of the most common solid tumours of childhood and is unique amongst paediatric cancers in that it results in the urinary excretion of catecholamine metabolites which are easily measured in spot urine samples and so is a condition for which screening may be considered. The continuing poor prognosis associated with late stage disease has stimulated great interest in this proposition. The Japanese have been undertaking pioneering studies of such screening since 1974 and since 1985, all 6 months old babies have been offered screening. Preliminary data would appear to suggest that screening is effective in greatly improving the survival of children with neuroblastoma. However there are difficulties associated with the interpretation of survival data since screening undoubtedly results in the detection of cases which would otherwise have remained 'silent', and the well known problems of lead-time and length-time bias complicate matters still further. The time is not yet ready for universal implementation of screening and further investigation is required.

Full text

PDF
S96

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auray-Blais C., Giguère R., Lemieux B. Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening. Med Pediatr Oncol. 1989;17(5):364–367. doi: 10.1002/mpo.2950170503. [DOI] [PubMed] [Google Scholar]
  2. BECKWITH J. B., PERRIN E. V. IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. Am J Pathol. 1963 Dec;43:1089–1104. [PMC free article] [PubMed] [Google Scholar]
  3. Birch J. M., Marsden H. B., Swindell R. Incidence of malignant disease in childhood: a 24-year review of the Manchester Children's Tumour Registry data. Br J Cancer. 1980 Aug;42(2):215–223. doi: 10.1038/bjc.1980.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brodeur G. M., Hayes F. A., Green A. A., Casper J. T., Wasson J., Wallach S., Seeger R. C. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 1987 Aug 15;47(16):4248–4253. [PubMed] [Google Scholar]
  5. Brodeur G. M., Seeger R. C., Schwab M., Varmus H. E., Bishop J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984 Jun 8;224(4653):1121–1124. doi: 10.1126/science.6719137. [DOI] [PubMed] [Google Scholar]
  6. Craft A. W., Amineddine H. A., Scott J. E., Wagget J. The Northern region Children's malignant disease registry 1968-82: incidence and survival. Br J Cancer. 1987 Dec;56(6):853–858. doi: 10.1038/bjc.1987.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Craft A. W., Dale G., McGill A., Seviour J., Spence E. M. Biochemical screening for neuroblastoma in infants: a feasibility study. Med Pediatr Oncol. 1989;17(5):373–378. doi: 10.1002/mpo.2950170505. [DOI] [PubMed] [Google Scholar]
  8. Evans A. E., D'Angio G. J., Propert K., Anderson J., Hann H. W. Prognostic factor in neuroblastoma. Cancer. 1987 Jun 1;59(11):1853–1859. doi: 10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  9. Evans A. E., D'Angio G. J., Randolph J. A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer. 1971 Feb;27(2):374–378. doi: 10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  10. Gansler T., Chatten J., Varello M., Bunin G. R., Atkinson B. Flow cytometric DNA analysis of neuroblastoma. Correlation with histology and clinical outcome. Cancer. 1986 Dec 1;58(11):2453–2458. doi: 10.1002/1097-0142(19861201)58:11<2453::aid-cncr2820581117>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  11. Hanai J., Kawai T., Sato Y., Takasugi N., Nishi M., Takeda T. Simple liquid-chromatographic measurement of vanillylmandelic acid and homovanillic acid in urine on filter paper for mass screening of neuroblastoma in infants. Clin Chem. 1987 Nov;33(11):2043–2046. [PubMed] [Google Scholar]
  12. Hanawa Y., Sawada T., Tsunoda A. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol. 1990;18(6):472–475. doi: 10.1002/mpo.2950180607. [DOI] [PubMed] [Google Scholar]
  13. Hann H. W., Levy H. M., Evans A. E. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res. 1980 May;40(5):1411–1413. [PubMed] [Google Scholar]
  14. Hayashi Y., Inaba T., Hanada R., Yamamoto K. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening. J Pediatr. 1988 Apr;112(4):567–571. doi: 10.1016/s0022-3476(88)80168-9. [DOI] [PubMed] [Google Scholar]
  15. Kellie S. J., Clague A. E., McGeary H. M., Smith P. J. The value of catecholamine metabolite determination on untimed urine collections in the diagnosis of neural crest tumours in children. Aust Paediatr J. 1986 Nov;22(4):313–315. doi: 10.1111/j.1440-1754.1986.tb02156.x. [DOI] [PubMed] [Google Scholar]
  16. Lemieux B., Auray-Blais C., Giguère R., Shapcott D., Scriver C. R. Newborn urine screening experience with over one million infants in the Quebec Network of Genetic Medicine. J Inherit Metab Dis. 1988;11(1):45–55. doi: 10.1007/BF01800056. [DOI] [PubMed] [Google Scholar]
  17. Look A. T., Hayes F. A., Shuster J. J., Douglass E. C., Castleberry R. P., Bowman L. C., Smith E. I., Brodeur G. M. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991 Apr;9(4):581–591. doi: 10.1200/JCO.1991.9.4.581. [DOI] [PubMed] [Google Scholar]
  18. Murphy S. B., Cohn S. L., Craft A. W., Woods W. G., Sawada T., Castleberry R. P., Levy H. L., Prorok P. C., Hammond G. D. Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening. Lancet. 1991 Feb 9;337(8737):344–346. doi: 10.1016/0140-6736(91)90957-q. [DOI] [PubMed] [Google Scholar]
  19. Nishi M., Miyake H., Takeda T., Shimada M., Takasugi N., Sato Y., Hanai J. Effects of the mass screening of neuroblastoma in Sapporo City. Cancer. 1987 Aug 1;60(3):433–436. doi: 10.1002/1097-0142(19870801)60:3<433::aid-cncr2820600326>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  20. Nishi M., Miyake H., Takeda T., Takasugi N., Sato Y., Hanai J., Kawai T. Cases of neuroblastoma missed by the mass screening programs. Pediatr Res. 1989 Dec;26(6):603–607. doi: 10.1203/00006450-198912000-00018. [DOI] [PubMed] [Google Scholar]
  21. Pritchard J., Barnes J., Germond S., Hartman O., de Kraker J., Lewis I., Lockwood L., Wallendszus K. Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group. Lancet. 1989 Aug 26;2(8661):514–515. doi: 10.1016/s0140-6736(89)92135-1. [DOI] [PubMed] [Google Scholar]
  22. Sawada T., Hirayama M., Nakata T., Takeda T., Takasugi N., Mori T., Maeda K., Koide R., Hanawa Y., Tsunoda A. Mass screening for neuroblastoma in infants in Japan. Interim report of a mass screening study group. Lancet. 1984 Aug 4;2(8397):271–273. doi: 10.1016/s0140-6736(84)90311-8. [DOI] [PubMed] [Google Scholar]
  23. Sawada T. Laboratory techniques and neuroblastoma screening. Lancet. 1988 Nov 12;2(8620):1134–1135. doi: 10.1016/s0140-6736(88)90545-4. [DOI] [PubMed] [Google Scholar]
  24. Sawaguchi S., Kaneko M., Uchino J., Takeda T., Iwafuchi M., Matsuyama S., Takahashi H., Nakajo T., Hoshi Y., Okabe I. Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan. Cancer. 1990 Nov 1;66(9):1879–1887. doi: 10.1002/1097-0142(19901101)66:9<1879::aid-cncr2820660905>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  25. Stiller C. A., Bunch K. J. Trends in survival for childhood cancer in Britain diagnosed 1971-85. Br J Cancer. 1990 Nov;62(5):806–815. doi: 10.1038/bjc.1990.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Taylor S. R., Blatt J., Costantino J. P., Roederer M., Murphy R. F. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer. 1988 Aug 15;62(4):749–754. doi: 10.1002/1097-0142(19880815)62:4<749::aid-cncr2820620418>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  27. Tuchman M., Fisher E. J., Heisel M. A., Woods W. G. Feasibility study for neonatal neuroblastoma screening in the United States. Med Pediatr Oncol. 1989;17(4):258–264. doi: 10.1002/mpo.2950170403. [DOI] [PubMed] [Google Scholar]
  28. Tuchman M., Lemieux B., Woods W. G. Screening for neuroblastoma in infants: investigate or implement? Pediatrics. 1990 Nov;86(5):791–793. [PubMed] [Google Scholar]
  29. Tuchman M., Ramnaraine M. L., Woods W. G., Krivit W. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics. 1987 Feb;79(2):203–205. [PubMed] [Google Scholar]
  30. Turkel S. B., Itabashi H. H. The natural history of neuroblastic cells in the fetal adrenal gland. Am J Pathol. 1974 Aug;76(2):225–244. [PMC free article] [PubMed] [Google Scholar]
  31. Zeltzer P. M., Marangos P. J., Parma A. M., Sather H., Dalton A., Hammond D., Siegel S. E., Seeger R. C. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet. 1983 Aug 13;2(8346):361–363. doi: 10.1016/s0140-6736(83)90342-2. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES